CARY, NC — December 12, 2014 — Biologics, a specialty pharmacy provider for Jakafi (ruxolitinib), is pleased to announce the U.S. Food and Drug Administration has approved Jakafi to treat patients with polycythemia vera (a chronic type of bone marrow disease) who have had an inadequate response to or are intolerant of hydroxyurea. The drug was approved by the FDA in November, 2011 for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.

In addition to providing Oncology Pharmacy Services, Biologics’ Patient Access Services team will support patients in need of financial assistance by working directly with charitable organizations, foundations and drug manufacturers’ assistance programs. To help streamline care and decrease the administrative burden for physicians, the team also performs benefits investigations and helps secure prior authorizations from payors.

Jakafi is commercially available immediately. Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. To send prescriptions via eScribe, physicians may search for Biologics within their EMR system.

Pharmacy name: Biologics
Street address: 13000 Weston Parkway, Suite 105, Cary, NC 27513
NCPDP: 3430369
NPI: 1487640314

About Biologics

Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payers and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk.

Biologics is part of McKesson Life Sciences (formerly McKesson Specialty Health), a division of McKesson Corporation empowering the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. Our combined organization will help better support patients and expedite access to oncology therapies. For more information, visit and

Media Contact
Claire Crye